NSAID Panel Could Give Naproxen Labeling Edge
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Arthritis and Drug Safety and Risk Management advisory committees on Feb. 10-11 will examine cardiovascular risk data for non-steroidal anti-inflammatory drugs, including meta-analyses indicating naproxen could have a better safety profile than other OTC ingredients ibuprofen and ketoprofen.
You may also be interested in...
NSAID Panel Highlights Challenge Of Getting Comparative Safety Claim
Does wide public health concern warrant flexibility in regulatory standards for safety claims? Advisory panel on cardiovascular risk of NSAIDs spotlights dual challenge of accurately determining drug risks and communicating risks in informative way.
NSAID Panel Highlights Challenge Of Getting Comparative Safety Claim
Does wide public health concern warrant flexibility in regulatory standards for safety claims? Advisory panel on cardiovascular risk of NSAIDs spotlights dual challenge of accurately determining drug risks and communicating risks in informative way.
NSAID Safety Review: FDA Panel Seeks Continued PRECISION From Pfizer
Pfizer’s long-term safety outcome study comparing Celebrex, ibuprofen and naproxen has its flaws, but FDA advisory committee says its data will be far superior to meta-analyses or observational studies.